Neuroimaging Technique Supports Reduction in Amyloid-Beta in Brains...
Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology .
Join the discussion below, or Read more at Earth Times.
#1 Mar 1, 2010
if the drink contains iron and folic acid then you might be onto a winner!
Add your comments below
|Drugmaker Elan plans to explore sale of company (Jun '13)||Jun '13||HumanSpirit||1|
|Plavix deal stokes pharma stocks; Biogen, Elan ... (Apr '06)||May '13||Yadiel||5|
|IPO Preview: ChemoCentryx (May '12)||May '12||Robson||1|
|Biogen's MS drug in question (Jul '11)||Jul '11||gumby||1|
|Patients taking Tysabri report improvement in p... (Sep '09)||Sep '09||tysabri_ftl||1|
|''Step Inside MS'' National Tour Brings First-o... (Sep '07)||Sep '07||Michelle||3|
Find what you want!
Search Elan Corporation Plc Forum Now
Copyright © 2017 Topix LLC